INTRODUCTION:

Schizophrenia is a severe and persistent neuropsychiatric disorder characterized by marked disturbances in perception, behavior, emotional regulation, and higher cognitive functions. It affects nearly one percent of the worldwide population and commonly begins during late adolescence or early adulthood, a period associated with critical brain maturation. The pathogenesis of schizophrenia is complex and involves the interaction of genetic vulnerability, environmental exposures, and abnormal neurodevelopmental processes. Clinically, symptoms are broadly categorized into three domains: positive manifestations such as hallucinations, delusional beliefs, and disorganized thinking; negative manifestations including diminished emotional expression, loss of motivation, social withdrawal, and reduced capacity for pleasure; and cognitive impairments affecting attention, learning, working memory, and executive control.¹ These symptom dimensions contribute significantly to long-term disability and impaired quality of life. Historically, the dopamine hypothesis has dominated the understanding of schizophrenia, proposing that excessive dopaminergic transmission within mesolimbic circuits underlies the development of positive psychotic symptoms. The neurodegenerative disease occurs with a progressive loss of a weak group of neurons that may differ among the inactive neuronal damage for the metabolic or lethal ailments.²Pharmacological models manipulating dopamine pathways successfully reproduce psychosis-like behaviors; however, these models inadequately explain the persistence of negative symptoms and cognitive dysfunction. More recently, experimental paradigms utilizing sub-anesthetic doses of ketamine, a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, have gained prominence as translational models of schizophrenia. In rodents, NMDA receptor blockade induces hyperlocomotion, stereotypic behaviors, deficits in prepulse inhibition, impaired social interaction, and learning and memory disturbances, closely resembling the behavioral and cognitive abnormalities observed in patients. Pharmacological management of schizophrenia primarily relies on first-generation and second-generation antipsychotic agents. Typical antipsychotics effectively control positive symptoms but frequently produce extrapyramidal adverse effects. Atypical antipsychotics offer broader symptom coverage with reduced motor toxicity; however, their use is limited by metabolic complications, including weight gain, dyslipidemia, glucose intolerance, and rare hematological toxicity. Furthermore, prolonged antipsychotic exposure has been associated with increased oxidative burden, which may contribute to neuronal vulnerability and disease progression. Drug-induced hyperexcitability arises when the delicate equilibrium between excitatory and inhibitory mechanisms in the central nervous system is disrupted^.3 These therapeutic limitations highlight the ongoing need to identify safer and more effective treatment strategies. In this context, growing interest has focused on natural bioactive compounds due to their antioxidant, anti-inflammatory, and neuroprotective potential, as well as their favorable safety profiles.⁴

Fundamental Features of Schizophrenia:

Schizophrenia presents as a complex clinical syndrome encompassing positive symptoms, negative symptoms, and cognitive impairment, each contributing to functional disability and long-term disease burden.

Positive Symptoms:

Positive symptoms represent abnormal experiences or behaviors that are not typically present in healthy individuals. These include hallucinations, delusional beliefs, and disorganization of thought and behavior. Auditory hallucinations are most frequently reported and often correspond with the content of delusional thinking. These manifestations usually respond favorably to antipsychotic pharmacotherapy, particularly agents targeting dopaminergic pathways.

Negative Symptoms:

Negative symptoms reflect a reduction or loss of normal emotional and motivational processes. Common features include avolition, anhedonia, alogia, social withdrawal, and blunted affect. These deficits are strongly associated with impaired psychosocial functioning, reduced treatment responsiveness, and poor long-term outcomes. Negative symptoms may arise as primary features of the illness or may develop secondary to medication effects, depressive states, or substance use.

Cognitive Impairment:

Cognitive dysfunction is a central component of schizophrenia and affects domains such as attention, working memory, executive functioning, processing speed, and learning ability. These impairments often appear before the onset of overt psychosis and tend to persist throughout the course of the disorder. Cognitive deficits significantly limit occupational performance, social integration, and overall quality of life.

Prognosis:

The clinical trajectory of schizophrenia is highly heterogeneous. A minority of individuals achieve sustained functional recovery, whereas many patients experience recurrent symptom exacerbations, residual impairments, and partial responsiveness to pharmacological interventions. Long-term prognosis is influenced by early diagnosis, treatment adherence, comorbid conditions, and availability of psychosocial support.⁵

ETIOLOGY:

Genetic Factors:

Extensive genetic investigations have confirmed that schizophrenia has a substantial heritable component; however, the precise genetic architecture and its relationship to clinical heterogeneity remain incompletely defined. Although inherited susceptibility significantly increases risk, concordance studies in identical twins demonstrate that genetic factors alone are insufficient to fully explain disease expression, emphasizing the contribution of non-genetic influences. Family, twin, and adoption studies consistently reveal a markedly higher prevalence of schizophrenia-spectrum traits among biological relatives of affected individuals compared with the general population. Concordance rates approach approximately 45–50% in monozygotic twins, whereas dizygotic twins exhibit substantially lower concordance, typically around 10–15%. Offspring of two affected parents show a greatly elevated lifetime risk, approaching nearly 40%, further supporting the role of familial aggregation while also indicating incomplete penetrance. Accumulating evidence suggests that different symptom dimensions may be governed by partially independent genetic mechanisms. Heritable components appear to differentially influence psychotic features, such as hallucinations and delusions, as well as cognitive impairment and negative symptom severity. Population-based twin analyses and pedigree studies indicate the presence of at least two genetic liability domains: one predominantly associated with positive symptom expression and another linked to neurocognitive dysfunction and motivational deficits. Moreover, schizophrenia-related personality traits and psychotic disorders occur more frequently among first-degree relatives of individuals with schizophrenia than among relatives of patients with affective disorders, highlighting the specificity of inherited vulnerability within the schizophrenia spectrum.

Developmental and Environmental Factors:

The neurodevelopmental framework remains a dominant model for understanding environmental contributions to schizophrenia risk. This concept proposes that disturbances during critical periods of brain maturation predispose individuals to later psychosis. Prenatal and perinatal adversities, including maternal infection, nutritional insufficiency, obstetric complications, fetal growth restriction, and maternal stress, have been consistently associated with increased susceptibility. Beyond early biological insults, psychosocial and environmental exposures also contribute significantly to disease risk. Childhood adversity, socioeconomic disadvantage, urban upbringing, and migration-related stress have been linked with higher incidence rates. Chronic social stressors, including discrimination, social isolation, and economic instability, may promote maladaptive cognitive processing and vulnerability to paranoid ideation.⁶Factors influencing the mental health of students that may contribute to the development or worsening of schizophrenia include unhealthy lifestyle patterns, poor academic habits, inadequate physical activity, disturbed sleep cycles, and elevated levels of stress, anxiety, or depressive symptoms. Establishing a supportive academic environment and implementing adolescent-focused mental health programs may help in early identification, prevention, and reduction of schizophrenia-related psychological complications^.7 Epidemiological data further indicate higher prevalence among individuals born during late winter or early spring and among offspring of older fathers, possibly due to increased rates of de novo genetic mutations or epigenetic alterations. Substance exposure during adolescence, particularly frequent use of high-potency cannabis, has emerged as an important modifiable risk factor for psychosis. Additional associations have been reported with traumatic brain injury, autoimmune disorders, epilepsy, and severe systemic infections, suggesting that immune and inflammatory mechanisms may interact with genetic susceptibility to influence disease onset.⁸

Concept of Oxidative Stress:

Oxidative stress refers to a pathological state in which excessive free radicals and reactive oxygen species overwhelm the body’s antioxidant defense systems. These reactive molecules are generated during normal metabolism as well as through exposure to environmental toxins, radiation, and pollutants. When their levels rise beyond physiological control, they can damage lipids, proteins, and DNA, contributing to neuronal dysfunction. Increasing evidence suggests that such oxidative imbalance plays a significant role in the pathophysiology of schizophrenia by promoting neuroinflammation, impairing neurotransmission, and accelerating neurodegenerative processes.⁹

Neurological Disorders and Oxidative Stress:

Oxidative stress has been widely implicated in the pathogenesis of several neurological and psychiatric disorders. An imbalance between reactive oxygen species and antioxidant defenses can disrupt neuronal integrity, alter synaptic signaling, and impair cognitive and behavioral functions. In the context of schizophrenia, increased oxidative burden has been associated with abnormalities in neurotransmitter systems, mitochondrial dysfunction, and neuroinflammatory processes. These alterations may contribute to the structural and functional brain changes observed in affected individuals, highlighting oxidative stress as an important mechanistic factor in the development and progression of schizophrenia.¹⁰

Types of Schizophrenia:

Contemporary diagnostic systems, including the DSM-5, categorize schizophrenia as a single diagnostic entity due to overlapping symptom profiles and limited reliability of subtype boundaries. Nevertheless, traditional subtypes continue to be discussed in academic and clinical contexts to describe dominant clinical patterns and symptom presentations.

Paranoid Type:

Paranoid schizophrenia is the most frequently encountered clinical pattern and is primarily characterized by prominent delusions and persistent auditory hallucinations. Individuals often retain relatively preserved cognitive functioning, speech organization, and emotional expression compared with other forms. Symptom onset may occur later in life, and patients may exhibit heightened suspiciousness, anxiety, or hostility. In severe cases, persecutory beliefs may increase the risk of self-harm or aggressive behavior.¹¹

Disorganized (Hebephrenic) Type:

This subtype is distinguished by markedly disorganized thinking, incoherent speech, and inappropriate or purposeless behavior. Emotional responses are often shallow or incongruent with situational context. Hallucinations and delusions, when present, are typically fragmented and poorly structured. The onset usually occurs during adolescence or early adulthood and is commonly associated with significant functional deterioration and impaired social integration.

Catatonic Type:

Catatonic schizophrenia is characterized by prominent psychomotor abnormalities, ranging from excessive motor activity and agitation to extreme immobility, mutism, posturing, and waxy flexibility. Alternating phases of stupor and excitement may occur. Due to reduced responsiveness and impaired self-care, affected individuals are at increased risk of dehydration, malnutrition, infection, and accidental injury.

Undifferentiated Type:

Undifferentiated schizophrenia is diagnosed when an individual exhibits clear psychotic features that do not consistently meet criteria for paranoid, disorganized, or catatonic patterns. This category reflects the heterogeneous and overlapping nature of symptom expression.

Residual Type:

Residual schizophrenia refers to patients with a documented history of psychotic episodes who currently demonstrate minimal positive symptoms but continue to experience persistent negative symptoms, cognitive impairment, and functional limitations.¹²

Signs and Symptoms:

The clinical presentation of schizophrenia encompasses a broad range of psychological and behavioral abnormalities that are commonly grouped into positive, negative, and cognitive symptom domains.

Positive Symptoms:

Positive symptoms reflect an exaggeration or distortion of normal mental functions. These manifestations include persistent delusional beliefs, sensory perceptions occurring in the absence of external stimuli (most commonly auditory hallucinations), and disorganized patterns of speech or thought that impair effective communication. Motor abnormalities, including catatonic features such as excessive agitation, rigidity, or prolonged immobility, may also be observed in some patients.¹³

Cognitive Symptoms:

Cognitive dysfunction represents a core component of schizophrenia and involves impairments in higher-order mental processes. Common deficits include reduced executive functioning, difficulty with planning and problem-solving, impaired attention, and compromised working memory, which limits the ability to temporarily store and manipulate information. These disturbances interfere with academic performance, occupational functioning, and social adaptation.

Negative Symptoms:

Negative symptoms are characterized by a reduction or absence of normal emotional expression and goal-directed behavior. Typical features include flattened affect, reduced verbal output (alogia), diminished motivation (avolition), decreased capacity to experience pleasure (anhedonia), and limited social engagement. Patients may demonstrate poor initiation of daily activities and reduced persistence in completing tasks. These symptoms are strongly associated with long-term disability and poor treatment response.¹⁴

Psychophysiology:

Individuals with schizotypal personality traits and schizophrenia exhibit a range of measurable psychophysiological abnormalities that reflect underlying disturbances in sensory processing, attention, and inhibitory control. These alterations are considered endophenotypes, as they represent heritable intermediate markers linking genetic vulnerability to clinical expression across the schizophrenia spectrum. One of the most consistently reported abnormalities is impaired sensory gating, commonly assessed using the P50 auditory evoked potential. Reduced suppression of the P50 response indicates difficulty in filtering repetitive or irrelevant sensory information, which may contribute to perceptual overload and cognitive fragmentation. This deficit has been observed not only in affected patients but also in unaffected first-degree relatives, suggesting strong heritability and involvement of nicotinic cholinergic mechanisms within hippocampal circuits ^15,16. Another prominent feature is diminished prepulse inhibition of the startle reflex, reflecting impaired automatic sensorimotor gating. Reduced prepulse inhibition indicates dysfunction in inhibitory neural pathways responsible for regulating behavioral responses to environmental stimuli. This phenomenon is mediated by complex cortico–striatal–pallido–thalamic networks and is consistently detected in schizophrenia, schizotypal personality disorder, and genetically related individuals. Abnormalities in oculomotor control are also frequently documented. Patients demonstrate impaired smooth-pursuit eye movements, increased corrective saccades, and reduced tracking accuracy, indicating disturbances in attentional and visual–motor integration processes. Deficits in antisaccade performance further reflect impaired executive control and inhibitory regulation of eye movements. These functions are regulated by interconnected frontal, temporal, and brainstem regions.Electrophysiological studies reveal additional cognitive processing abnormalities, including reduced P300 and N400 event-related potential amplitudes, which reflect deficits in attentional allocation, stimulus evaluation, and semantic processing. Structural neuroimaging findings have linked these electrophysiological changes to volume reductions in temporal cortical regions, particularly within the superior temporal gyrus.Sustained attention deficits are commonly identified using continuous performance tasks. Individuals with schizotypal traits may perform adequately under simple task conditions; however, performance deteriorates significantly as task complexity increases, such as under divided attention or degraded stimulus conditions. These impairments are associated with dysfunction of fronto-striatal circuits involved in attentional regulation and cognitive control^17,18,19 Collectively, these psychophysiological abnormalities support the continuum model of psychosis and provide valuable biomarkers for early detection and therapeutic monitoring.

Pathophysiology of Schizophrenia:

Schizophrenia arises from a complex interaction between neurotransmitter imbalances, abnormal neural connectivity, and disrupted neurodevelopmental processes. These converging mechanisms contribute to the diverse clinical manifestations involving positive, negative, and cognitive symptom domains.

Dopaminergic Dysregulation:

Altered dopamine signaling remains a central neurochemical feature of schizophrenia. Excessive dopaminergic activity within mesolimbic circuits is strongly associated with the development of hallucinations and delusional thinking. In contrast, reduced dopamine transmission in mesocortical pathways, particularly within the prefrontal cortex, is linked to motivational deficits, emotional blunting, impaired working memory, and executive dysfunction.

Four major dopaminergic pathways are functionally relevant in schizophrenia:

· Nigrostriatal pathway: Regulates voluntary movement; dopamine blockade in this pathway contributes to extrapyramidal motor adverse effects associated with antipsychotic therapy.

· Mesolimbic pathway: Hyperactivity in this pathway mediates positive psychotic symptoms.

· Mesocortical pathway: Hypoactivity contributes to negative symptoms and cognitive impairment.

· Tuberoinfundibular pathway: Dopamine inhibition increases prolactin secretion, leading to endocrine disturbances such as galactorrhea, menstrual irregularities, sexual dysfunction, and reduced libido.

Glutamatergic Abnormalities:

Growing evidence supports a critical role of glutamatergic dysfunction in schizophrenia, particularly reduced activity of N-methyl-D-aspartate (NMDA) receptors. Pharmacological blockade of NMDA receptors using agents such as ketamine or phencyclidine produces behavioral, cognitive, and perceptual disturbances that resemble schizophrenia, reinforcing the glutamate hypothesis. NMDA receptor hypofunction disrupts cortical–subcortical communication and may secondarily alter dopaminergic signaling.

Serotonergic Modulation:

Serotonin pathways also contribute to the pathophysiology of schizophrenia. Activation of serotonergic receptors, particularly 5-HT₂A receptors, influences dopamine release in cortical and limbic regions and modulates perception and cognition. The psychotomimetic effects of serotonergic hallucinogens provided early evidence for this mechanism. Many second-generation antipsychotics exert therapeutic benefit through combined antagonism of dopamine D₂ and serotonin 5-HT₂A receptors, improving symptom control and tolerability.²⁰

Structural and Functional Brain Alterations:

Neuroimaging studies consistently demonstrate reduced gray matter volume in the prefrontal cortex, temporal lobes, hippocampus, and thalamus. White matter abnormalities suggest impaired neural connectivity and altered information processing. Ventricular enlargement has also been reported, reflecting neurodevelopmental disruption or progressive tissue loss. These changes correlate with cognitive dysfunction and functional disability.

Neurodevelopmental Contributions:

Schizophrenia is increasingly recognized as a disorder of abnormal brain maturation. Genetic susceptibility combined with prenatal or early-life insults, such as maternal infection, nutritional deficiency, obstetric complications, and early exposure to environmental toxins, may interfere with neuronal migration, synaptic refinement, and cortical organization. These developmental abnormalities create latent vulnerability that manifests clinically during adolescence or early adulthood.²¹

Lifestyle and Self-Care Interventions:

Lifestyle modification strategies represent an important adjunctive component in the comprehensive management of schizophrenia. These non-pharmacological approaches may complement standard therapeutic interventions and contribute to overall maternal well-being.

Physical Activity:

Regular participation in moderate physical exercise has been reported to positively influence mood and reduce depressive manifestations through modulation of neurochemical pathways and stress-related hormonal responses. Activities such as walking and yoga may be particularly suitable for postpartum women due to their safety, accessibility, and psychological benefits.

Nutrition:

Optimal nutritional intake is essential for maintaining physiological stability and supporting neuropsychological function. A balanced diet comprising adequate macronutrients and micronutrients plays a vital role in sustaining energy levels and emotional equilibrium. Professional dietary guidance may assist postpartum mothers in achieving appropriate nutritional status and improving overall health outcomes.

Sleep Hygiene:

Sleep disturbances are frequently associated with PPD and may exacerbate symptom severity. Implementation of structured sleep hygiene measures—including consistent sleep–wake schedules, reduction of environmental disruptions, and avoidance of stimulants before bedtime—can enhance sleep quality and support recovery.²²

Diagnosis:

The clinical identification of schizophrenia is often complex because its manifestations overlap with several other psychiatric conditions and display wide variability in severity, progression, and therapeutic response. Although current diagnostic frameworks define schizophrenia as a single disorder, substantial differences exist among individuals with respect to symptom expression, disease course, and functional impairment. Clinical assessment is therefore based on standardized diagnostic criteria established in the Diagnostic and Statistical Manual of Mental Disorders (DSM).Diagnosis requires the persistence of multiple psychotic features for a continuous period of at least four weeks. These features may include fixed false beliefs, perceptual disturbances occurring without external stimuli, incoherent or illogical speech patterns, markedly abnormal motor behavior, and negative features such as restricted emotional expression, limited verbal communication, and reduced goal-directed activity.²³At least one of the presenting features must consist of delusions, hallucinations, or disorganized speech. In addition, measurable deterioration in occupational performance, interpersonal functioning, or self-care abilities supports diagnostic confirmation.The onset pattern varies considerably across individuals. Some patients experience sudden emergence of overt psychotic symptoms, whereas others undergo a prolonged prodromal phase characterized by gradual behavioral changes, emotional instability, and subtle cognitive decline. In many cases, motivational deficits and cognitive impairment may appear several years before the first acute psychotic episode, making early diagnosis challenging.Recent progress in neuroimaging, genomics, and molecular neuroscience has facilitated the identification of genetic susceptibility regions and potential neurobiological indicators linked to schizophrenia. While no validated biomarker is currently available for routine clinical application, ongoing research suggests that combined biological signatures may eventually enhance early detection, improve risk prediction, and support personalized treatment selection within precision medicine approaches²⁴

Treatment of Schizophrenia:

The management of schizophrenia aims to reduce symptom burden, minimize relapse frequency, enhance functional capacity, and support community reintegration. As full recovery to premorbid levels of functioning is uncommon, long-term care typically requires an integrated approach combining pharmacological therapy with structured psychosocial interventions. Although antipsychotic agents constitute the central component of treatment, many individuals continue to experience residual behavioral, emotional, or cognitive difficulties, underscoring the value of adjunctive strategies such as psychotherapy, family-based interventions, skills training, and occupational rehabilitation .Initiation of pharmacotherapy at an early stage of illness, particularly soon after the first psychotic manifestation, is associated with more favorable long-term outcomes, as this phase represents a period of heightened neural plasticity and disease progression risk. Medicinal plants are used for various research purposes. It has been reported that traditional system has immune potential against various diseases. More than 13,000 plants have been studied for various pharmacological properties^.25 The presence of substance use, including psycho-stimulants, alcohol, tobacco, and excessive caffeine intake, can compromise therapeutic efficacy and increase relapse probability through pharmacokinetic interactions and neurobiological stress. Consistent medication adherence, regular follow-up, and individualized treatment monitoring are therefore essential for maintaining clinical stability and reducing recurrence.

Classical Pharmacological Approaches in The Treatment of Schizophrenia:

Antipsychotic agents constitute the mainstay of schizophrenia treatment and primarily exert therapeutic effects through antagonism or partial agonism of dopamine D₂ receptors, with additional modulation of serotonergic pathways. These drugs effectively reduce hallucinations and delusions but demonstrate limited efficacy in alleviating negative symptoms and cognitive dysfunction, often necessitating prolonged maintenance therapy. Approximately one-third of patients exhibit inadequate response to standard antipsychotics and are classified as treatment-resistant; clozapine remains the most effective therapeutic option in this population.

Therapeutic benefit is largely mediated by dopamine blockade within mesolimbic circuits, whereas non-selective dopamine inhibition in other pathways contributes to adverse reactions, including extrapyramidal symptoms, endocrine disturbances, sedation, and cardiovascular complications. Second-generation antipsychotics partially mitigate these limitations through combined D₂ and 5-HT₂A receptor antagonism, offering improved tolerability profiles. Nevertheless, metabolic adverse effects such as weight gain, insulin resistance, and dyslipidemia continue to pose significant clinical challenges.²⁶

Ayurvedic formulations are traditionally recognized for their rejuvenating and adaptogenic properties, which enhance the body’s resilience to physiological and psychological stress. Herbal agents such as Guduchi (Tinospora cordifolia) and Madhuyashti (Glycyrrhiza glabra) have been reported to possess antioxidant, immunomodulatory, and neuroprotective activities that may support cognitive function and neural stability. These properties are particularly relevant in the context of schizophrenia, where oxidative stress, neuroinflammation, and impaired stress adaptation are implicated in disease pathophysiology. Experimental studies, including those employing model organisms, suggest that such herbs may improve stress tolerance and cellular defense mechanisms, indicating their potential as supportive therapeutic agents in neuropsychiatric disorders²⁷

Recent efforts toward neuroscience-based nomenclature aim to classify psychotropic medications according to their pharmacodynamic mechanisms rather than traditional therapeutic labels, facilitating more rational drug selection and personalized treatment strategies.

Future Directions in Schizophrenia Management:

Despite significant progress in antipsychotic drug development, the clinical management of schizophrenia continues to be limited by persistent cognitive impairment, partial treatment responsiveness, and long-term metabolic and neurological adverse effects. Current pharmacotherapies primarily target dopaminergic and serotonergic neurotransmission and are effective in reducing positive symptoms; however, their impact on negative symptoms and cognitive decline remains modest. These challenges highlight the necessity for innovative therapeutic approaches that extend beyond conventional mono-target strategies. Future research should focus on multi-modal interventions that integrate standard antipsychotics with agents possessing antioxidant, anti-inflammatory, and neuroprotective properties in order to enhance therapeutic efficacy and minimize adverse outcomes. Natural bioactive compounds and phytochemicals represent promising adjunctive candidates due to their favorable safety profiles and capacity to modulate oxidative stress, neuroinflammation, mitochondrial dysfunction, and synaptic plasticity. Neurological impairment represents a major and growing health concern worldwide, with brain-related disorders contributing substantially to overall disease burden. Among these conditions, schizophrenia is a significant neuropsychiatric disorder characterized by structural and functional brain alterations, cognitive deficits, and behavioral disturbances. Increasing evidence indicates that neurobiological changes—including oxidative stress, neuroinflammation, and neurotransmitter imbalance—play a crucial role in its pathogenesis, underscoring the importance of understanding brain dysfunction in relation to schizophrenia.²⁸ Advances in precision medicine, including pharmacogenomics, proteomics, and biomarker-driven treatment selection, may facilitate individualized therapy optimization and improve clinical outcomes. Various Drugs are being developed that target these pathological causes.²⁹Identification of predictive biomarkers may enable early intervention, improve treatment stratification, and reduce trial-and-error prescribing practices. Additionally, growing recognition of the gut–brain axis and microbiome–immune interactions has opened new avenues for therapeutic modulation aimed at regulating neuroinflammatory pathways and cognitive function. Collectively, these emerging strategies may contribute to the development of safer, more effective, and personalized treatment paradigms for schizophrenia.³⁰

CONCLUSIONS:

Schizophrenia is a complex neuropsychiatric disorder arising from the interaction of genetic vulnerability, abnormal neurodevelopment, neurotransmitter imbalance, and environmental influences. While dopaminergic dysregulation plays a major role in the manifestation of positive symptoms, persistent negative symptoms and cognitive deficits are increasingly attributed to glutamatergic dysfunction, serotonergic modulation, oxidative stress, immune activation, and impaired neural connectivity.Although antipsychotic medications remain essential for symptom control, their limited efficacy in cognitive and negative domains, along with significant adverse effect burden, underscores the need for therapeutic innovation. Future treatment strategies should prioritize multi-target approaches that incorporate neuroprotective, anti-inflammatory, and antioxidant mechanisms alongside conventional pharmacotherapy. Continued advancement in biomarker identification, translational research, and personalized medicine will be critical for improving diagnostic accuracy, optimizing treatment selection, and enhancing long-term functional outcomes. A deeper understanding of disease mechanisms remains fundamental to the development of safer and more effective interventions for schizophrenia.

REFERENCES:

1. Ben-Azu B, Aderibigbe AO, Adeoluwa OA, Iwalewa EO. Ethanol Extract of Terminalia Ivorensis Stem Bark Attenuates Positive, Negative, And Cognitive Symptoms of psychosis in Experimental Models. Journal of Pharmaceutical Research International. 2016; 1–4.

2. Kalaiselvi S, Manimaran V, Damodharan N. Nanoparticle as a powerful tool to penetrate the Blood-brain barrier in the treatment of neurodegenerative disease: Focus on recent advances. Research Journal of Pharmacy and Technology. 2020 May 1; 13(5): 2135-43.

3. Preethi PJ, Padmini K, Srikanth J, Lohita M, Swetha K. Screening Models for CNS Stimulant Drugs: A Review. Asian Journal of Pharmaceutical Research. 2013; 3(3): 144-50.

4. Chatterjee M, Seema S, Reena K, Verma AK, Gautam P. Evaluation of the Antipsychotic Potential of Panax Quinquefolium in A Ketamine-Induced Psychosis Model in Mice. Neurochemical Research. 2012;37(4):759–770.

5. Fatani BZ, Aldawod R, Alhawaj A, Alsadah S, Slais FR, Alyaseen EN, Et Al. Schizophrenia: Etiology, Pathophysiology and Management. The Egyptian Journal of Hospital Medicine. 2017; 69(6): 2640–2646.

6. Rubeša G, Gudelj L, Kubinska N. Etiology of Schizophrenia and Therapeutic Options. Psychiatria Danubina. 2011;23(3):308–315.

7. Suvitha S, Kanimozhi S, Kanimozhi S, Kathiyayani M, Madhuri K. Literature Review related to Association between Mental Health and Academic Performance among Adolescents. A and V Pub International Journal of Nursing and Medical Research. 2023 Dec; 2(4): 130-2.

8. Team ET. Guideline For Pharmacological Treatment of Schizophrenia. 2022.

9. Jadhav Sameer S, Salunkhe Vijay R, Magdum Chandrakant S. Daily Consumption of Antioxidants: -Prevention of Disease Is Better Than Cure. Asian J. Pharm. Res. 2013 Jan; 3(1): 33-9.

10. Uttara B, Singh AV, Zamboni P, Mahajan R. Oxidative Stress and Neurodegenerative Diseases: A Review of Upstream and Downstream Antioxidant Therapeutic Options. Current Neuropharmacology. 2009 Mar 1; 7(1): 65-74.

11. American Psychiatric Association. Diagnostic And Statistical Manual of Mental Disorders. 5th Ed. Washington DC: American Psychiatric Publishing; 2013.

12. Moran M. Analysis Supports DSM-5 Changes to Schizophrenia Criteria.

13. Gebreegziabhere Y, Habatmu K, Mihretu A, Cella M, Alem A. Cognitive Impairment in People with Schizophrenia: An Umbrella Review. European Archives of Psychiatry and Clinical Neuroscience. 2022; 272(7): 1139–1155.

14. Mccutcheon RA, Krystal JH, Howes OD. Dopamine And Glutamate in Schizophrenia: Biology, Symptoms and Treatment. World Psychiatry. 2020; 19(1): 15–33.

15. Siever LJ, Davis KL. The Pathophysiology of Schizophrenia Spectrum Disorders. American Journal of Psychiatry. 2004; 161(3): 398–413.

16. Freedman R, Adler LE, Myles-Worsley M, Et Al. Inhibitory Gating of Auditory Evoked Responses In Schizophrenia. Archives Of General Psychiatry. 1996; 53: 1114–1121.

17. Cadenhead KS, Light GA, Geyer MA, Braff DL. Sensory Gating Deficits in Schizotypal Personality Disorder. American Journal of Psychiatry. 2000; 157: 55–59.

18. Salisbury DF, Voglmaier MM, Seidman LJ, Mccarley RW. P300 Abnormalities In Schizotypal Personality Disorder. Biological Psychiatry. 1996; 40: 165–172.

19. Trestman RL, Horvath TB, Kalus O, Et Al. Event-Related Potentials in Schizotypal Personality Disorder. Journal Of Neuropsychiatry and Clinical Neurosciences. 1996; 8:33–40.

20. Fadgyas-Stanculete M, Capatina OO. Glutamate-Based Therapeutic Strategies for Schizophrenia. International Journal of Molecular Sciences. 2025; 26(9): 4331.

21. Okubo R, Okada M, Motomura E. NMDA Receptor Dysfunction in Schizophrenia and Treatment Resistance. Biomolecules. 2024; 14(9): 1128.

22. Bakshi I, Dey S, Katta S, Raut AJ. Understanding Postpartum Depression: A Comprehensive Review. International Journal for Multidisciplinary Research. 2024; 6(2): 191-4.

23. Abrahamyan Empson L, Et Al. Urbanicity and Psychosis Risk. Early Intervention in Psychiatry. 2020; 14: 398–409.

24. Amato D, Beasley CL, Hahn MK, Vernon AC. Neuroadaptations to Antipsychotic Drugs. Neuroscience And Biobehavioral Reviews. 2017; 76: 317–335.

25. Papaiah S, Babu VR, Rao TS, Jackson DD, Senthilkumar KL. Memory Enhancing Property of Santalum Album L. On Mice. Research Journal of Pharmacology and Pharmacodynamics. 2010 Feb 28; 2(1): 94-6.

26. Stępnicki P, Kondej M, Kaczor AA. Current Concepts and Treatments of Schizophrenia. Molecules. 2018; 23(8): 2087.

27. Sahu D, Bhushan S, Das D, Debnath SK, Barik L, Meena V, Singh V, Dixit AK, Prasad PV. Potential Ayurvedic Herbs for Neurodegenerative Diseases: A Review. Research Journal of Pharmacology and Pharmacodynamics. 2021 Apr 1; 13(2): 69-74.

28. Kumar S, Kumar D, Gulia S, Thakur M. Traumatic Brain Injury: Role in Induction and Progression of Neurodegenerative Disorders. Research Journal of Pharmacy and Technology. 2024 Apr 1; 17(4): 1909-15.

29. Patel CK, Panigrahi B, Badmanaban R, Patel CN. Biochemical Origins of Alzheimer’s Disease with Treatment Techniques. Research Journal of Pharmacology and Pharmacodynamics. 2010 Feb 28; 2(1): 33-8.

30. A Mustafa AM, Abdou K, Et Al. Natural Compounds for Schizophrenia Management. Naunyn-Schmiedeberg’s Archives of Pharma

Received on 30.01.2026 Revised on 02.03.2026

Accepted on 28.03.2026 Published on 10.07.2026

Available online from July 14, 2026

Res.J. Pharmacology and Pharmacodynamics.2026;18(3):289-296.

DOI: 10.52711/2321-5836.2026.00039

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.